Ars Pharmaceuticals Inc Insider Trading

SPRY

Last 12 months

Insiders sold $1.95M and bought nothing on the open market.

15% of the selling was scheduled in advance under 10b5-1 plans. Chief Business Officer Justin Chakma sold $1.48M on Nov 12, 2025, 100% of their stake, outside a plan. The last open-market buy by an executive or director was in Sep 2023.

Net open-market

−$1.95M

0 buys · 4 sales

Under a 10b5-1 plan

15%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

Sep 2023

Sep 29, 2023

Get an email when SPRY's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jun 12	Eric Karas Chief Commercial Officer	Sold10b5-1 plan	25,000	$10.00	250K	67%	Form 4
Jun 12	Alexander A Fitzpatrick Chief Legal Officer	Sold10b5-1 plan	3,355	$10.00	34K	3.6%	Form 4
Nov 13, 2025	Brian Dorsey Chief Operating Officer	SoldNo plan	21,828	$8.71	190K	67%	Form 4
Nov 12, 2025	Justin Chakma Chief Business Officer	SoldNo plan 2 parts	166,380	$8.87 average	$1.48M	100%	Form 4
Aug 21, 2025	Richard E Lowenthal President and CEO	Sold10b5-1 plan	50,000	$14.49	725K	0.4%	Form 4
Aug 21, 2025	Kathleen D. Scott Chief Financial Officer	Sold10b5-1 plan	12,500	$15.00	188K	41%	Form 4
Aug 19, 2025 – Aug 20, 2025	Sarina Tanimoto Chief Medical Officer	Sold10b5-1 plan 2 parts	50,000	$14.08 average	704K	0.4%	Form 4
Jul 1, 2025	Eric Karas Chief Commercial Officer	Sold10b5-1 plan	15,000	$16.99	255K	59%	Form 4
Jun 27, 2025	James E Flynn Large holder	SoldNo plan 2 parts	740,149	$18.46 average	$13.7M	7.0%	Form 4
Jun 18, 2025	Eric Karas Chief Commercial Officer	Sold10b5-1 plan	15,000	$16.00	240K	66%	Form 4
May 20, 2025	Alexander A Fitzpatrick Chief Legal Officer	SoldNo plan	102,969	$14.10	$1.45M	53%	Form 4
May 20, 2025	Brent L Saunders Director	SoldNo plan	120,000	$14.25	$1.71M	100%	Form 4
May 20, 2025	Kathleen D. Scott Chief Financial Officer	SoldNo plan	50,000	$14.10	705K	76%	Form 4
Apr 7, 2025	Laura Shawver Director	Sold10b5-1 plan	50,002	$12.30	615K	19%	Form 4
Mar 20, 2025	Eric Karas Chief Commercial Officer	Sold10b5-1 plan	10,000	$14.00	140K	57%	Form 4
Mar 5, 2025 – Mar 6, 2025	Laura Shawver Director	Sold10b5-1 plan 2 parts	50,000	$11.21 average	560K	19%	Form 4
Feb 3, 2025	Laura Shawver Director	Sold10b5-1 plan	50,000	$12.31	616K	19%	Form 4
Jan 6, 2025	Laura Shawver Director	Sold10b5-1 plan	50,000	$11.10	555K	19%	Form 4
Dec 17, 2024	Sarina Tanimoto Chief Medical Officer	Sold10b5-1 plan 2 parts	100,000	$11.67 average	$1.17M	0.9%	Form 4
Dec 17, 2024	Richard E Lowenthal President and CEO	Sold10b5-1 plan 2 parts	100,000	$11.67 average	$1.17M	0.9%	Form 4
Dec 12, 2024 – Dec 13, 2024	Justin Chakma Chief Business Officer	SoldNo plan 2 parts	144,605	$12.23 average	$1.77M	51%	Form 4
Dec 11, 2024 – Dec 12, 2024	Brian Dorsey Chief Operating Officer	Sold10b5-1 plan 2 parts	40,000	$12.35 average	494K	87%	Form 4
Dec 10, 2024	Justin Chakma Chief Business Officer	SoldNo plan	50,000	$13.15	658K	27%	Form 4
Dec 10, 2024	Sarina Tanimoto Chief Medical Officer	Sold10b5-1 plan 2 parts	100,000	$13.17 average	$1.32M	0.9%	Form 4
Dec 10, 2024	Richard E Lowenthal President and CEO	Sold10b5-1 plan 2 parts	100,000	$13.17 average	$1.32M	0.9%	Form 4
Dec 4, 2024 – Dec 6, 2024	Justin Chakma Chief Business Officer	SoldNo plan 3 parts	144,640	$14.11 average	$2.04M	51%	Form 4
Dec 2, 2024 – Dec 4, 2024	Laura Shawver Director	Sold10b5-1 plan 4 parts	200,000	$13.44 average	$2.69M	49%	Form 4
Dec 2, 2024 – Dec 4, 2024	Eric Karas Chief Commercial Officer	Sold10b5-1 plan 2 parts	10,000	$14.04 average	140K	64%	Form 4
Dec 2, 2024 – Dec 3, 2024	Justin Chakma Chief Business Officer	SoldNo plan 2 parts	90,000	$13.43 average	$1.21M	40%	Form 4
Nov 25, 2024 – Nov 27, 2024	Justin Chakma Chief Business Officer	SoldNo plan 3 parts	100,000	$14.12 average	$1.41M	42%	Form 4
Nov 19, 2024	Richard E Lowenthal President and CEO	Sold10b5-1 plan 2 parts	100,000	$13.95 average	$1.4M	0.9%	Form 4
Nov 19, 2024	Sarina Tanimoto Chief Medical Officer	Sold10b5-1 plan 2 parts	100,000	$13.95 average	$1.4M	0.9%	Form 4
Nov 12, 2024	Sarina Tanimoto Chief Medical Officer	Sold10b5-1 plan 4 parts	100,000	$16.85 average	$1.68M	0.8%	Form 4
Nov 12, 2024	Richard E Lowenthal President and CEO	Sold10b5-1 plan 4 parts	100,000	$16.85 average	$1.68M	0.8%	Form 4
Nov 11, 2024 – Nov 12, 2024	Deerfield Private Design Fund Iii, L.p. Large holder	SoldNo plan 8 parts	563,270	$18.01 average	$10.1M	5.1%	Form 4

Jun 1210b5-1 plan
Eric Karas
Chief Commercial Officer · sold 25,000 at $10.00
250K
67% of stake
Jun 1210b5-1 plan
Alexander A Fitzpatrick
Chief Legal Officer · sold 3,355 at $10.00
34K
3.6% of stake
Nov 13, 2025No plan
Brian Dorsey
Chief Operating Officer · sold 21,828 at $8.71
190K
67% of stake
Nov 12, 2025No plan
Justin Chakma
Chief Business Officer · sold 166,380 at avg $8.87
$1.48M
100% of stake
Aug 21, 202510b5-1 plan
Richard E Lowenthal
President and CEO · sold 50,000 at $14.49
725K
0.4% of stake
Aug 21, 202510b5-1 plan
Kathleen D. Scott
Chief Financial Officer · sold 12,500 at $15.00
188K
41% of stake
Aug 19, 2025 – Aug 20, 202510b5-1 plan
Sarina Tanimoto
Chief Medical Officer · sold 50,000 at avg $14.08
704K
0.4% of stake
Jul 1, 202510b5-1 plan
Eric Karas
Chief Commercial Officer · sold 15,000 at $16.99
255K
59% of stake
Jun 27, 2025No plan
James E Flynn
Large holder · sold 740,149 at avg $18.46
$13.7M
7.0% of stake
Jun 18, 202510b5-1 plan
Eric Karas
Chief Commercial Officer · sold 15,000 at $16.00
240K
66% of stake
May 20, 2025No plan
Alexander A Fitzpatrick
Chief Legal Officer · sold 102,969 at $14.10
$1.45M
53% of stake
May 20, 2025No plan
Brent L Saunders
Director · sold 120,000 at $14.25
$1.71M
100% of stake
May 20, 2025No plan
Kathleen D. Scott
Chief Financial Officer · sold 50,000 at $14.10
705K
76% of stake
Apr 7, 202510b5-1 plan
Laura Shawver
Director · sold 50,002 at $12.30
615K
19% of stake
Mar 20, 202510b5-1 plan
Eric Karas
Chief Commercial Officer · sold 10,000 at $14.00
140K
57% of stake
Mar 5, 2025 – Mar 6, 202510b5-1 plan
Laura Shawver
Director · sold 50,000 at avg $11.21
560K
19% of stake
Feb 3, 202510b5-1 plan
Laura Shawver
Director · sold 50,000 at $12.31
616K
19% of stake
Jan 6, 202510b5-1 plan
Laura Shawver
Director · sold 50,000 at $11.10
555K
19% of stake
Dec 17, 202410b5-1 plan
Sarina Tanimoto
Chief Medical Officer · sold 100,000 at avg $11.67
$1.17M
0.9% of stake
Dec 17, 202410b5-1 plan
Richard E Lowenthal
President and CEO · sold 100,000 at avg $11.67
$1.17M
0.9% of stake
Dec 12, 2024 – Dec 13, 2024No plan
Justin Chakma
Chief Business Officer · sold 144,605 at avg $12.23
$1.77M
51% of stake
Dec 11, 2024 – Dec 12, 202410b5-1 plan
Brian Dorsey
Chief Operating Officer · sold 40,000 at avg $12.35
494K
87% of stake
Dec 10, 2024No plan
Justin Chakma
Chief Business Officer · sold 50,000 at $13.15
658K
27% of stake
Dec 10, 202410b5-1 plan
Sarina Tanimoto
Chief Medical Officer · sold 100,000 at avg $13.17
$1.32M
0.9% of stake
Dec 10, 202410b5-1 plan
Richard E Lowenthal
President and CEO · sold 100,000 at avg $13.17
$1.32M
0.9% of stake
Dec 4, 2024 – Dec 6, 2024No plan
Justin Chakma
Chief Business Officer · sold 144,640 at avg $14.11
$2.04M
51% of stake
Dec 2, 2024 – Dec 4, 202410b5-1 plan
Laura Shawver
Director · sold 200,000 at avg $13.44
$2.69M
49% of stake
Dec 2, 2024 – Dec 4, 202410b5-1 plan
Eric Karas
Chief Commercial Officer · sold 10,000 at avg $14.04
140K
64% of stake
Dec 2, 2024 – Dec 3, 2024No plan
Justin Chakma
Chief Business Officer · sold 90,000 at avg $13.43
$1.21M
40% of stake
Nov 25, 2024 – Nov 27, 2024No plan
Justin Chakma
Chief Business Officer · sold 100,000 at avg $14.12
$1.41M
42% of stake
Nov 19, 202410b5-1 plan
Richard E Lowenthal
President and CEO · sold 100,000 at avg $13.95
$1.4M
0.9% of stake
Nov 19, 202410b5-1 plan
Sarina Tanimoto
Chief Medical Officer · sold 100,000 at avg $13.95
$1.4M
0.9% of stake
Nov 12, 202410b5-1 plan
Sarina Tanimoto
Chief Medical Officer · sold 100,000 at avg $16.85
$1.68M
0.8% of stake
Nov 12, 202410b5-1 plan
Richard E Lowenthal
President and CEO · sold 100,000 at avg $16.85
$1.68M
0.8% of stake
Nov 11, 2024 – Nov 12, 2024No plan
Deerfield Private Design Fund Iii, L.p.
Large holder · sold 563,270 at avg $18.01
$10.1M
5.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch SPRY, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with SPRY

CompareIntrinsic value

GYREGyre Therapeutics Inc.

$4.44+0.00%18

CYTKCytokinetics, Incorporated

$63.60+2.07%10

TBPHTheravance Biopharma Inc.

No recent price82

ASRTAssertio Holdings Inc.

$9.09+0.28%10

SEPNSepterna, Inc.

$47.88+9.57%46

AGIOAgios Pharmaceuticals Inc.

$31.38+0.58%40

ZVRAZevra Therapeutics, Inc.

$11.17+8.87%83

XNCRXencor Inc.

$35.01+14.28%0

Held by ETFs

SPRY is in 17 US ETFs. The largest of them, with SPRY's weight in each:

Spot a number that looks wrong? Check it in SPRY's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SPRY

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.